Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash & Equivalents (2016 - 2026)

Pharma-Bio Serv's Cash & Equivalents history spans 16 years, with the latest figure at $5.8 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 21.12% year-over-year to $5.8 million; the TTM value through Jan 2026 reached $5.8 million, down 21.12%, while the annual FY2025 figure was $3.4 million, 50.07% down from the prior year.
  • Cash & Equivalents reached $5.8 million in Q1 2026 per PBSV's latest filing, up from $3.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $15.4 million in Q1 2022 to a low of $2.1 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $7.7 million, with a median of $6.8 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: tumbled 79.85% in 2023, then soared 127.22% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $14.5 million in 2022, then fell by 27.77% to $10.4 million in 2023, then plummeted by 35.22% to $6.8 million in 2024, then tumbled by 50.07% to $3.4 million in 2025, then soared by 70.56% to $5.8 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Cash & Equivalents are $5.8 million (Q1 2026), $3.4 million (Q4 2025), and $4.0 million (Q3 2025).